ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1544

Increased Risk of Severe Infection in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: A Population-based Trend Analysis

Kai Zhao1, J. Antonio Avina-Zubieta2, Hui Xie3, Natasha Dehghan4 and John Esdaile2, 1Arthritis Research Canada, Coquitlam, BC, Canada, 2Arthritis Research Canada, Vancouver, BC, Canada, 3Simon Fraser University, Richmond, BC, Canada, 4University of British Columbia, Vancouver, BC, Canada

Meeting: ACR Convergence 2023

Keywords: Administrative Data, ANCA associated vasculitis, Infection

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1534–1553) Vasculitis – ANCA-Associated Poster II: Epidemiology, Outcomes, & Classification

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a group of multisystem inflammatory diseases. One of the most serious and common side-effects of GC and immunosuppressant drug use is infection. No studies have explained the change in risk over time. What’s more, findings from previous studies may not accurately represent the risk of infection due to AAV as many studies are based on hospitalized patients, small sample sizes, prevalent cohorts, different approaches to defining AAV, and/or limited adjustment of potential confounders. To address these research gaps, we conducted a large population-based study of all patients with incident AAV. We aimed to answer three questions: a) what is the independent risk of first severe infection due to AAV, b) the trajectory of the risk for severe infection in AAV compared to the matched controls , and c) the trajectory of the rate of repeated severe infections in AAV compared to the matched controls.

Methods: We conducted an age- and sex-matched cohort study of all patients with incident AAV using administrative health data from British Columbia, Canada. The primary outcome was the first severe infection after AAV onset necessitating hospitalization or occurring during hospitalization. We used multivariate Cox proportional hazard models to compare time to the onset of infection and estimate hazard ratios. The secondary outcome was the longitudinal counts of severe infection. We used two-part zero-inflated Poisson mixed model (ZIPMM) with splines to assess the secular trend in the infection count.

Results: One in three patients with newly diagnosed AAV developed severe infection (3.8-fold when compared to non-AAV).AAV patients had the highest risk of severe infection during the first 30 days of diagnosis, which dropped at different rates before and after the second year. However, among those at risk for severe infections, the rate of repeated severe infections stayed the same over time within the first two years of AAV diagnosis and even increased over time afterward.

Conclusion: In summary, this is the first large comprehensive population-based study evaluating the risk of infection with incident AAV. Our study demonstrates that one in three AAV patients developed severe infections, demonstrating that the diagnosis of AAV is an independent risk factor for severe infection. ZIPMM spline model suggests that an AAV patient who has experienced infection should be treated differently and properly from one who experiences no infection. Having a more precise understanding of which individuals are likely to experience infection and develop repeated infections could help to ensure a more efficient use of healthcare dollars and perhaps a more accurate attribution of intervention effects. This research is a further step towards a deeper understanding of the prevention, screening and treatment of infection over time. We recommend a closer surveillance for severe infections in AAV patients and routine risk checks for severe infections for AAV patients after diagnosis. Further studies are also warranted to further clarify the relative contribution of inflammation and medication, and to identify modifiable risk factors for infections in AAV.

Supporting image 1

Comparing secular trends in the rate of severe infections in AAV and non-AAV.

Supporting image 2

Secular trend of infection count in AAV relative to the general population using ZIPMM spline model. Abbreviations: AAV, Antineutrophil cytoplasmic antibody-associated Vasculitis; OR = odds ratio. RR = Rate ratio; 95% CI = 95% confidence interval. RRs and 95% CI are individual-specific (or conditional) estimates.


Disclosures: K. Zhao: None; J. Avina-Zubieta: None; H. Xie: None; N. Dehghan: None; J. Esdaile: None.

To cite this abstract in AMA style:

Zhao K, Avina-Zubieta J, Xie H, Dehghan N, Esdaile J. Increased Risk of Severe Infection in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: A Population-based Trend Analysis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/increased-risk-of-severe-infection-in-patients-with-antineutrophil-cytoplasmic-antibody-associated-vasculitides-a-population-based-trend-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-risk-of-severe-infection-in-patients-with-antineutrophil-cytoplasmic-antibody-associated-vasculitides-a-population-based-trend-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology